国瑞健康(02329) - 2023 - 年度业绩

Audit Committee - The audit committee has been established and is composed of independent non-executive directors, with Liu Chengjiang serving until January 29, 2024, after which it will consist of Chen Jinrong and Deng Zhidong[4]. Financial Review - The company has reviewed the unaudited full-year results for the year ending December 31, 2023, along with its risk management framework and internal control systems[4]. Board Composition - The board of directors includes five executive directors and two independent non-executive directors as of the announcement date[5].